Clinical trials: Fusion of Joint
Ankylosing Spondylitis
An Observational, Retrospective, Multicenter, National Study for the Monitoring of Subjects Who Participated in the LoadET Clinical Trial
Previous studies suggest that an increase in doses of weekly etanercept from 50 mg to 100 mg improves the efficacy of the treatment in patients with cutaneous psoriasis, rheumatoid arthritis, and psoriatic arthritis.
- Trial name
- RELOADET (NCT01793285)
- Testing
- ETANERCEPT
- Where
- 15 sites in Spain
- Volunteers
- 85 people
- Sponsor
- Pfizer
Joint Disease
Post Market Clinical Follow-Up Study Protocol for PROFEMUR® TL Modular Femoral Stems
Sponsor is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) marketed in the European Union (EU) .
- Trial name
- NCT02239783
- Testing
- total hip arthroplasty implant
- Where
- Canada
- Volunteers
- 143 people
- Sponsor
- MicroPort Orthopedics Inc.
Ankle Arthritis, Arthritis Foot
The Use of a Dynamic Sustained Compression Intramedullary Nail for Tibiotalocalcaneal Arthrodesis
The purpose of this study is to determine the clinical efficacy of a novel sustained dynamic compression intramedullary nail for tibiotalocalcaneal (TTC) arthrodesis utilizing longitudinal weight-bearing computed tomographic…
- Trial name
- NCT04831645
- Testing
- DynaNail, Tibiotalocalcaneal Arthrodesis
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- MedShape, Inc
Axial Spondyloarthritis, Psoriatic Arthritis
Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): Spanish Multicenter, Retrospective, Real World Evidence Study
This was a multicenter, retrospective, and non-interventional study using secondary data captured in the Electronic Health Records (EHRs).
- Trial name
- NCT05677542
- Testing
- secukinumab
- Where
- 3 sites in Spain
- Volunteers
- 758 people
- Sponsor
- Novartis Pharmaceuticals
Axial Spondyloarthritis, Ankylosing Spondylitis
Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for Efficacy
The goal of this clinical trial is to find out if the study drug will work as a new therapy for axSpA patients. This study is placebo-controlled, and evaluates if study drug can treat symptoms of axSpA, including global disease…
- Conditions
- Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpA, Nr-axSpA
- Trial name
- V-SPINE (NCT06526377)
- Testing
- vilamakitug
- Volunteers
- 150 people
- Sponsor
- XBiotech, Inc.
Axial Spondyloarthritis
A Study of Brodalumab in Subjects With Axial Spondyloarthritis (axSpA)
To evaluate the efficacy of Brodalumab in axSpA (ankylosing spondylitis [AS] and non-radiographic axial spondyloarthritis [nr-axSpA]) subjects compared to placebo, as measured by the proportion of axSpA subjects achieving an…
- Trial name
- NCT02985983
- Testing
- Brodalumab
- Where
- 48 sites in Japan, South Korea and 1 more
- Volunteers
- 159 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Spondylitis, Ankylosing
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis
The purpose of this study is to provide 16-week efficacy, safety and tolerability data versus placebo to support the use of secukinumab 150 mg by subcutaneous (s.c.) self-administration with or without a loading regimen and…
- Trial name
- MEASURE4 (NCT02159053)
- Testing
- Secukinumab
- Where
- 90 sites in United States, Australia and 17 more
- Volunteers
- 350 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis
Effects of Etanercept on the Heart, Veins and Thickness of Certain Major Arteries In Ankylosing Spondylitis Patients
Study to assess whether etanercept therapy is able to increase flow-mediated vasodilatation in AS, and whether etanercept can modify the intima-media thickness (IMT) in these patients
- Trial name
- CREST (NCT00910273)
- Testing
- etanercept
- Where
- 4 sites in Italy
- Volunteers
- 34 people
- Sponsor
- Pfizer
Axial Spondyloarthritis (AxSpA)
Retrospective Case-Control Study for Developing an Artificial Intelligence (AI) Tool for Lesion Detection Using Magnetic Resonance Imaging (MRI) and Clinical Variables for Early Diagnosis of Axial Spondyloarthritis (axSpA)
The goal of this observational study is to develop and validate an Artificial Intelligence (AI) tool that allows the lesion detection and early diagnosis of axial spondyloarthritis (axSpA) based on Magnetic Resonance Imaging…
- Trial name
- InnovaDetect (NCT06591481)
- Where
- 7 sites in Jordan, Saudi Arabia and 2 more
- Volunteers
- 925 people, healthy volunteers welcome
- Sponsor
- Ángel Alberich Bayarri
Axial Spondyloarthritis, Ankylosing Spondylitis
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing…
- Conditions
- Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpa, Nr-axSpa
- Trial name
- BE MOVING (NCT04436640)
- Testing
- Bimekizumab
- Where
- 75 sites in United States, Belgium and 12 more
- Volunteers
- 508 people
- Sponsor
- UCB Biopharma SRL
Osteoarthritis, Rheumatoid Arthritis
Web-based Support to Manage Arthritis Pain
Development of an interactive, online pain self-management program for adults who suffer from pain associated with osteoarthritis, rheumatoid arthritis, Ankylosing spondylitis, and other arthritic conditions (e.g., psoriatic…
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Other Arthritic Conditions (e.g., Psoriatic Arthritis)
- Trial name
- NCT01463189
- Testing
- painACTION: Arthritis
- Where
- United States
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- Inflexxion, Inc.
Ankylosing Spondylitis
Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)
This study is a population-based cohort of patients with ankylosing spondylitis (AS) from general medical practices in the UK, France, and Germany with a nested case control component to assess associations between drug exposures…
- Trial name
- NCT01077843
- Testing
- Etoricoxib, Other Cox-2 inhibitors, Other Non-selective NSAIDs
- Volunteers
- 27,381 people
- Sponsor
- Organon and Co
Ankylosing Spondylitis
Study Evaluating Etanercept in Subjects With Ankylosing Spondylitis in Spain
The purpose of this study was to evaluate efficacy and safety of etanercept 100 mg (50 mg twice a week) compared with 50 mg once a week in adult subjects with ankylosing spondylitis (AS) and previous failure to usual practice…
- Trial name
- Loadet (NCT00873730)
- Testing
- etanercept
- Volunteers
- 108 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Tibiotalar Arthrodesis, Subtalar Arthrodesis
Evaluation of Trinity Evolution in Patients Undergoing Foot and Ankle Fusion
The purpose of this study is to utilize Trinity Evolution as a graft source in foot/ankle fusions and to follow the subjects to measure the clinical outcomes and fusion rate.
- Conditions
- Tibiotalar Arthrodesis, Subtalar Arthrodesis, Calcaneocuboid Arthrodesis, Talonavicular Arthrodesis
- Trial name
- TAF (NCT00988338)
- Testing
- Trinity Evolution
- Where
- 10 sites in United States
- Volunteers
- 106 people
- Sponsor
- Orthofix Inc.
Ankylosing Spondylitis
Study Evaluating Predictors of Response in Patients With Ankylosing Spondylitis
The objective of this observational study is to determine the incidence of response in patients with predictive factors of major clinical response in active ankylosing spondylitis (AS) in patients who start anti-tumor necrosis…
- Trial name
- PRETEA (NCT00900796)
- Testing
- Treatment switching
- Where
- Spain
- Volunteers
- 132 people
- Sponsor
- Pfizer
Moderate and Severe Rheumatoid Arthritis
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis
This is a phase Ⅱ, placebo-controlled, multicenter, dynamic randomized, double blind study of the efficacy and safety of RC18, a recombinant human B lymphocyte stimulating factor receptor-antibody fusion protein in subjects with…
- Trial name
- NCT02882087
- Testing
- RC18 160 mg plus MTX
- Where
- China
- Volunteers
- 60 people
- Sponsor
- RemeGen Co., Ltd.
Ankylosing Spondyloarthritis
Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis
The purpose of this trial is to demonstrate the clinical efficacy at week 16; and to demonstrate safety and tolerability of secukinumab compared to placebo in patients with ankylosing spondylitis at week 16 and long term safety…
- Trial name
- NCT02896127
- Testing
- Secukinumab
- Where
- 44 sites in China, Czechia and 2 more
- Volunteers
- 458 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis
Study Of Celecoxib Or Diclofenac For Efficacy and Safety In Chinese Patients With Ankylosing Spondylitis
This is a local, multicenter, randomized, active comparator, double-blind, parallel group study with extension will be conducted to evaluate the efficacy and safety of celecoxib versus diclofenac SR in the treatment of Chinese…
- Trial name
- NCT00762463
- Testing
- Celecoxib, Diclofenac SR
- Where
- 5 sites in China
- Volunteers
- 240 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Sacroiliac Joint Dysfunction
SAIF: Sacroiliac Fusion Study
The purpose of the SAIF study is to evaluate the SImmetry Sacroiliac Joint Fusion System for fusion and pain reduction of the SI joint.
- Trial name
- SAIF (NCT02064322)
- Testing
- SImmetry Implant
- Volunteers
- 2 people
- Sponsor
- Zyga Technology, Inc.
Rheumatoid Arthritis, Psoriatic Arthritis
A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct )
This is a five year, post-marketing observational study to follow-up patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis who are treated with HUMIRA (adalimumab).
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
- Trial name
- ProAct (NCT01078558)
- Volunteers
- 5,940 people
- Sponsor
- AbbVie (prior sponsor, Abbott)